Published in Cancer Res on October 01, 2006
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T (2013) 1.68
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta (2007) 1.64
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell (2014) 1.43
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 1.41
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33
Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol Cells (2009) 1.28
C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov (2011) 1.27
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 1.27
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res (2010) 1.16
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene (2010) 1.13
Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol Endocrinol (2010) 1.06
BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res (2010) 1.05
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev (2012) 1.04
Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics (2010) 1.03
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
Signal control through Raf: in sickness and in health. Cell Res (2011) 0.97
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Molecular nevogenesis. Dermatol Res Pract (2011) 0.97
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov (2012) 0.96
Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. J Biol Chem (2010) 0.96
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia (2009) 0.94
Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci U S A (2013) 0.93
PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.). PLoS One (2013) 0.92
Genetics of melanoma. Front Genet (2013) 0.91
C-RAF mutations confer resistance to RAF inhibitors. Cancer Res (2013) 0.91
Protein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropin. Mol Pharmacol (2009) 0.89
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLoS One (2013) 0.88
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation. J Biol Chem (2013) 0.86
Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions. Arch Dermatol (2011) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) (2007) 0.85
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res (2014) 0.85
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases (2011) 0.85
Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma. Oncogene (2012) 0.84
Narrowing the knowledge gaps for melanoma. Ups J Med Sci (2012) 0.84
Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res (2011) 0.84
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One (2011) 0.84
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol (2016) 0.83
GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. Eur J Med Res (2010) 0.83
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Cancer Res (2010) 0.83
In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression. J Exp Clin Cancer Res (2010) 0.83
Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol (2007) 0.83
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther (2015) 0.82
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer (2011) 0.82
MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A (2013) 0.81
Investigation of cAMP microdomains as a path to novel cancer diagnostics. Biochim Biophys Acta (2014) 0.81
Cancer: Melanoma troops massed. Nature (2009) 0.81
The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One (2014) 0.81
Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World J Exp Med (2015) 0.80
Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration. J Biol Chem (2012) 0.79
Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cell Signal (2015) 0.79
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
New insight puts CRAF in sight as a therapeutic target. Cancer Discov (2011) 0.77
Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag (2015) 0.77
Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol (2016) 0.77
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol (2015) 0.76
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology (2010) 0.76
Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway. Mol Cancer Res (2015) 0.75
MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. Sci Rep (2017) 0.75
RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells. Oncol Lett (2011) 0.75
Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Elife (2016) 0.75
NMR metabolic fingerprints of murine melanocyte and melanoma cell lines: application to biomarker discovery. Sci Rep (2017) 0.75
The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas. PLoS Genet (2017) 0.75
Aberrant expression of kallikrein-related peptidase 7 is correlated to human melanoma aggressiveness by stimulating cell migration and invasion. Mol Oncol (2017) 0.75
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene (2017) 0.75
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell (2006) 2.20
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2012) 2.01
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem (2006) 1.94
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res (2005) 1.93
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Metagenomic marine nitrogen fixation--feast or famine? Trends Microbiol (2005) 1.89
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol (2005) 1.66
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J Med Chem (2009) 1.65
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 1.63
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 1.61
Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet (2011) 1.60
Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem (2003) 1.58
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
The role of B-RAF in melanoma. Cancer Metastasis Rev (2005) 1.53
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res (2007) 1.50
Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol (2008) 1.50
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med (2010) 1.36
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer (2007) 1.33
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33